Aims To determine the effects of dietary changes in amount and type of carbohydrate on 1,5-anhydroglucitol levels.
Introduction
The role of diet in the development of diabetes and its impact on biomarkers of glycaemia is an ongoing area of debate. Recently the OmniHeart Trial showed that a diet with a higher proportion of carbohydrate decreased insulin sensitivity compared with a diet that had a higher proportion of unsaturated fat [1] . Subsequently, the Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes (OmniCarb) trial showed that, in the context of a diet with high carbohydrate (CHO) content, a low compared with a high glycaemic index (GI) decreased insulin sensitivity and increased fasting glucose levels [2] .
1,5-anhydroglucitol (1,5-AG) is a monosaccharide found primarily in foods [3] . In people with diabetes, blood concentration of 1,5-AG is an emerging marker of hyperglycaemia and glycaemic variability. l,5-AG is inversely associated with blood glucose concentrations as a result of competitive inhibition by glucose in the proximal tubule [4] and is thought to be useful for intermediate-term monitoring of glycaemic variability in people with diabetes [5] . In epidemiological studies, low concentrations have been associated with greater diabetes risk [6, 7] and, in the setting of diabetes with retinopathy, chronic kidney disease [7] [8] [9] and cardiovascular disease [10, 11] . In people without diabetes, 1,5-AG may reflect carbohydrate digestion [12, 13] . Little is known about the effects of diet on 1,5-AG, particularly the effects of dietary carbohydrate. The effects of diet on 1,5-AG represent an important source of exogenous variability that remain uncharacterized.
The present study was conducted as an ancillary study to the OmniCarb trial, a randomized crossover dietary intervention study in overweight and obese adults without diabetes. In the setting of the OmniCarb trial, our objectives were to quantify and compare the effects on 1,5-AG concentrations of a diet that reduced GI, a diet that reduced proportion of carbohydrates or a diet that reduced both.
Participants and methods
The rationale, design and main results from the OmniCarb trial have been published previously [2] . In brief, the OmniCarb trial was an investigator-initiated trial sponsored by the National Heart, Lung, and Blood Institute. The OmniCarb trial used a crossover design to compare the effects of altering the quantity or quality of carbohydrates in the context of the DASH diet on cardiovascular disease risk factors [14] . The DASH diet is a pattern of healthy eating that emphasizes fruits, vegetables and lowfat dairy foods with reduced intake of saturated fat, total fat and cholesterol. Also emphasized in the original DASH diet were whole grains, poultry, fish and nuts, with smaller amounts of red meat, sweets and sugar-containing beverages [14] . The primary outcomes of the original study were: insulin sensitivity (Matsuda index) [15] ; LDL cholesterol; HDL cholesterol; triglycerides; and systolic blood pressure.
We conducted an ancillary study to the OmniCarb trial that used stored plasma specimens to examine the effects of amount and type of carbohydrates on 1,5-AG.
Study participants
Participants were recruited from areas around Boston, Massachusetts and Baltimore, Maryland. The trial began in August 2009 and was completed in December 2010. Participants were aged ≥30 years with a BMI ≥ 25 kg/m 2 , and had systolic and diastolic blood pressures ranging from 120 to 159 mmHg and 80 to 99 mmHg, respectively. Individuals with a diagnosis of diabetes or cardiovascular disease were excluded from the trial, as were those with a fasting glucose concentration >125 mg/dl (6.9 mmol/l) [2] . In the present study, we further excluded four people for whom stored blood samples were not available.
Trial intervention
The trial had a four-period, randomized crossover design, in which participants were fed each one of four diets in turn for 5 weeks with 2-week washout periods between diets [2] . The four diets were: (1) high proportion of carbohydrate (CHO) (58% kcal) with high (≥65) GI (CG); (2) low CHO (40% kcal) with low (≤45) GI (cg); (3) high CHO with low GI (Cg); and (4) low CHO with high GI (cG). Details of the diets are provided in Table S1 . All meals were provided to participants at the study centres. The diets included common US foods, but were low in saturated fat, cholesterol and sodium, and rich in fruits, vegetables, fibre, potassium and other minerals, similar to the DASH diet [14] . Calorie targets were determined at baseline based on the body size, sex and physical activity level of each participant. Adjustments were made to the caloric level throughout the duration of the study to ensure that participants' weight remained within 2% of their baseline weight. Participants were asked to avoid changes in activity levels and alcohol use during the course of the study. Furthermore, each participant listed protocol and nonprotocol foods in a diary throughout the study.
Primary outcome: 1,5-anhydroglucitol
The two trial centres used the same specimen collection protocols. Fresh whole-blood samples were collected at baseline and at the end of each 5-week feeding period (2009) (2010) in EDTA tubes. These specimens were immediately spun using a refrigerated centrifuge for 20 min at 1500 9 g, and then transferred into cryovials for storage. Plasma specimens were stored in specimen freezers and maintained at -80°C. In 2012, plasma specimens underwent a single thaw cycle for measurement of 1,5-AG (GlycoMark, Winston-Salem, NC, USA), using a Siemens Dimension Vista 1500 chemical analyser (Siemens Healthcare Diagnostics, Glasgow, DE, USA) via a two-step enzymatic method [16] What's new?
• 1,5-anhydroglucitol (1,5AG) is an emerging marker of hyperglycaemia that is reduced in the blood in the setting of elevated glucose levels.
• 1,5AG is originally derived from the diet but the impact of diet on this marker is not known; this impact could have implications for its interpretation.
• In a tightly controlled feeding study in adults without diabetes, we show that both type and proportion of carbohydrate influence 1,5AG levels independently of hyperglycaemia.
• This finding contradicts the long-standing notion that 1,5-AG remains at constant concentrations in the blood in the absence of hyperglycaemic excursions.
that used spectrophotometry to quantify its concentration. The inter-assay coefficient of variation was 2.4% (mean 14.291 mg/dl or 87.1 lmol/l). Previous research suggests that 1,5-AG is robust to a single freeze-thaw cycle [17] .
Secondary outcomes: glucose and insulin
Glucose and insulin were also measured at baseline and at the end of each diet period as part of the original OmniCarb trial protocol [2] . Serum was collected from fasting participants prior to and 2 h after the administration of a 75-g oral glucose bolus. Serum was collected in serum separator tubes, the contents of which were allowed to clot for 30 min, and was then centrifuged in a refrigerated environment for 20 min at 1500 9 g. Glucose and insulin were measured shortly after collection throughout the duration of the trial (2009-2010) after a single freeze-thaw.
Baseline characteristics
Baseline characteristics of the participants were determined via questionnaire, laboratory specimens, and physical examination. BMI was calculated using height and weight measurements. Waist circumference was measured at the level of the umbilicus. Total cholesterol, triglycerides and HDL cholesterol were measured in serum. Baseline hypertensive status (yes or no) was determined using an average of three baseline blood pressure measurements; hypertension was defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
Statistical analysis
We compared change in 1,5-AG from baseline (end-of-period minus baseline) after consumption of each of the 5-week diets. We further compared the changes in 1,5-AG among the diets, specifically examining the effects of: (1) reducing GI in the context of either a low CHO (cg vs cG) or high CHO (Cg vs CG) and (2) reducing %CHO in the context of either a low GI (cg vs Cg) or high GI (cG vs CG), or changing both factors simultaneously in the opposite (cG vs cG) or same (cg vs CG) directions. Comparisons were plotted for visual presentation. Comparisons were made with generalized estimating equation regression models and a Huber and White robust variance estimator [18] , which assumed an exchangeable working correlation matrix. These analyses were repeated for our secondary outcomes; namely, 5-week change in fasting glucose, fasting insulin, 2-hour glucose and 2-hour insulin levels. Missing data were rare (n = 4) and were evenly distributed between diets and dietary periods.
We also performed a cross-sectional analysis of baseline 1,5-AG and fasting glucose, fasting insulin, 2-h glucose and 2-h insulin levels. We calculated Pearson's correlation coefficient (r) and performed linear regression with adjustment for age, sex and race.
Sensitivity analyses were performed to evaluate changes in 1,5-AG in the absence of known glucose excursions. In one sensitivity analysis, we restricted the study population to a group of 37 participants who had glucose measured at the end of each dietary period,~14 times over the course of 12 daytime hours. In this subsample, none of the participants had a glucose excursion measured above 160 mg/dl (8.9 mmol/l), the threshold after which serum glucose is thought to influence 1,5-AG concentrations [4] . In another sensitivity analysis, we restricted to a population of participants, who maintained a fasting glucose <126 mg/dl (7 mmol/l) and a 2-h oral glucose tolerance test result <200 mg/dl (11.1 mmol/l) in all serum measurements during the course of the trial (this represents a maximum of five fasting glucose and five 2-h glucose measurements over a 6-month period; N = 120).
Finally, we performed a sensitivity analysis in study participants with a diabetes-defining glucose measurement at one point during the trial, i.e. at least one measured fasting glucose ≥126 mg/dl (7 mmol/l) or a 2-h oral glucose tolerance test ≥200 mg/dl (11.1 mmol/l; N = 39).
All analyses were performed using STATA version 14.0 (Stata Corp., College Station, TX, USA). Statistical significance was defined as P < 0.05. The study protocol was approved by institutional review boards at Johns Hopkins University, Brigham and Women's Hospital, and the Harvard School of Public Health.
Results
The mean (SD) age of the 159 participants included in the present study was 53 (11) year, 53% were women, and 52% were non-Hispanic black ( Table 1 Changes from baseline 1,5-AG concentrations measured at the end of each dietary period were compared with those at baseline ( Table 2) . Regardless of the assigned diet during the OmniCarb trial, there were significant reductions in 1,5-AG, ranging from -2.4 to -3.7 lg/mL (-14.6 to -22.5 lmol/l) over the course of each feeding period (all P values for difference from baseline < 0.001). By contrast, there were inconsistent baseline changes in fasting glucose with only the high GI/high CHO and high GI/low CHO diets showing baseline reductions of -2.5 mg/dl (CG, P = 0.02; -0.14 mmol/l) and -2.0 mg/dl (cG, P = 0.03; -0.11 mmol/l). There were no significant changes in 2-h glucose or fasting insulin during each of the diet periods; however, there was a marginal reduction in 2-h insulin levels during the high GI/low CHO diet (-5.1 lU/mL or -36.6 pmol/l; P = 0.05).
ª 2017 Diabetes UK End-of-period measurements of 1,5-AG were compared among diets to examine the effects of changing GI, proportion of carbohydrate, or both factors on plasma concentrations of 1,5-AG (Fig. 1) . Reducing GI led to 1,5-AG reduction of approximately -1 lg/ml (-6 lmol/l) in both low and high CHO diets (both P <0.001). By contrast, reducing the proportion of carbohydrate only significantly lowered 1,5-AG in the context of a high GI diet by -0.5 lg/ ml (-3 lmol/l; P = 0.002), but not in the context of a low GI diet (-0.2 lg/ml or -1.2 lmol/l; P = 0.18). Results were additive, in that when both factors were reduced simultaneously (cg vs CG), 1,5-AG levels decreased by -1.3 lg/mL (-7.9 lmol/l; P <0.001).
Cross-sectional comparison of 1,5-AG with other markers of glucose homeostasis are shown in Table 3 . In this population without diabetes, 1,5-AG was not strongly correlated with fasting glucose, 2-h glucose, fasting insulin or 2-h insulin.
In a sensitivity analysis restricted to the 37 participants who had glucose measured over a 12-h period without a single measurement above 160 mg/dl (8.9 mmol/l), results were virtually identical to those of our main analysis (Table S2) . Similarly, results were unchanged when restricted to participants (N = 120) with fasting glucose measures <126 mg/dl (7.0 mmol/l) and 2-h oral glucose tolerance test measures <200 mg/dl (11.1 mmol/l) at all measurements Data are mean (SD), unless otherwise specified. *Defined as baseline systolic blood pressure mmHg ≥140 or diastolic blood pressure ≥90 mmHg. †Does not sum to 100% due to rounding. Convert triglycerides from mg/dl to mmol/l by multiplying by 0.0113. Convert HDL and LDL cholesterol from mg/dl to mmol/l by multiplying by 0.0259. throughout the trial (Table S3 ). The main findings were also nearly identical in participants who had at least one measured fasting glucose ≥126 mg/dl (7.0 mmol/l) or a 2-h oral glucose tolerance test ≥200 mg/dl (11.1 mmol/l) during the trial (N = 39; Table S4 ).
Discussion
The present study represents one of the only intervention studies to examine the effects of diet on 1,5-AG. We found that adopting a healthy, DASH-style diet significantly reduced 1,5-AG concentrations during the trial. Furthermore, reducing either or both GI and CHO led to reductions in 1,5-AG concentration in an additive fashion. These effects were further observed in subpopulations with glucose excursions below the threshold necessary to lower 1,5-AG, implying that diet is an independent determinant of 1,5-AG concentrations among people without diabetes. 1,5-AG is the 1-deoxy form of glucose, a monosaccharide derived from foods [4] . It is found in high quantities in soybeans, rice, bread, beef and other plant sources [3] . After consumption, 1,5-AG remains metabolically stable and is distributed throughout body organs and tissues [4] . 1,5-AG is freely filtered by glomeruli at a rate of 5-10 mg/ml each day and, in a healthy person without diabetes, it is almost entirely reabsorbed by the proximal renal tubule [4] ; however, when glucose rises above the renal threshold for glucose, typically >160-180 mg/dl (8.9-10 mmol/l) [4, 19] , the excess glucose competes with 1,5-AG for reabsorption in the proximal tubule, which in turn increases urine excretion of 1,5-AG and lowers blood concentrations [4, 20] .
The interpretation of 1,5-AG variation among adults without diabetes is unclear. It is thought that some of the differences among individuals may be accounted for by differences in renal reabsorption of 1,5-AG [21] . It is also possible that 1,5-AG varies as a result of factors that affect food digestion (for example, microbiota) [12] or nutrient absorption [13] . By controlling diets and performing withinparticipant comparisons, we are able to isolate the contribution of changes in carbohydrates on 1,5-AG concentrations, independent of mechanisms related to renal or gastrointestinal processes. Comparisons are organized by dietary factor: glycaemic index (GI), proportion of carbohydrates, or both factors. CG, high carbohydrate/high GI diet; Cg, high carbohydrate/low GI diet; cG, low carbohydrate/ high GI diet; cg, low carbohydrate/low GI diet. Convert 1,5-AG from lg/mL to lmol/l by multiplying by 6.0918. The present study excluded people with a diagnosis of diabetes. As a result, it would be highly unlikely that glucose concentrations would exceed the renal threshold necessary for glycosuria. This was evident in our subsample of 37 participants, who were monitored for 12 h at the end of each diet period; none of these participants had a serum glucose concentration exceeding 160 mg/dl (8.9 mmol/l); thus, the reductions in 1,5-AG compared with baseline with each of the four diets suggest that diet alters 1,5-AG concentrations independently of glycaemia in people without diabetes. This is further supported by the observation that fasting glucose concentrations decreased from baseline with the two high GI diets (CG and cG). In a population with diabetes, higher blood glucose with subsequent glycosuria would cause 1,5-AG to be reduced, but this was not observed in our population of adults without diabetes.
The dietary effects on 1,5-AG observed in the present trial suggest that there may be important dietary determinants of 1,5-AG. It is unclear if these effects are relevant for the interpretation of 1,5-AG in people with diabetes. Advocates of 1,5-AG have recommended that it be used for short-term (2-week) assessment of glycaemic control in response to new treatment regimens [22] . Others have suggested it be used to monitor hyperglycaemic excursions in people with diabetes, especially those with an HbA 1c concentration < 64 mmol/mol (8%) [5, [23] [24] [25] . 1,5-AG may be useful for diabetes management to the extent that plasma concentrations are maintained at a stable level as a result of relatively constant, dietary consumption of 1,5-AG, which is in equilibrium with renal excretion [3] ; however, the present study suggests that short-term changes in diet may directly affect 1,5-AG concentrations in the blood by a mean of -2.4 lg/mL (-14.6 lmol/l) when changing from a typical US diet (participants' baseline diet) to the high GI/high CHO OmniCarb diet and further by -1.3 lg/ml (-7.9 lmol/l) when modestly reducing carbohydrate quantity and quality (cg vs CG). While these effects may be large enough to be problematic for individuals with a 1,5-AG close to 10 lg/mL (60.9 lmol/ l), a threshold espoused in clinical algorithms, it remains unclear if these dietary effects would be sufficiently large to alter the interpretation of the 1,5-AG in the setting of diabetes, where the overwhelming determinant of 1,5-AG is likely to be elevated glucose levels.
The present study has several limitations. All of the four randomized diets were healthy diets, i.e. variants of the DASH diet. While it is likely that the baseline diets of participants were less healthy than the randomized diets, changes from baseline should be interpreted cautiously because this was not a randomized comparison. We could not examine specific diet components, and the 1,5-AG content of the diets was not known. The study also did not include anyone with diabetes. Nevertheless, studies of 1,5-AG in people without diabetes provided an opportunity to examine the effects of dietary changes on 1,5-AG, independently of changes in overt hyperglycaemia [6, 26] . Moreover, while it would seem likely that the observed effects of diet on 1,5-AG concentration would also occur in people with diabetes, it is possible that the magnitude of effect would be dwarfed by the direct effects of hyperglycaemia and glycosuria.
The present study has a number of strengths. The study population was quite diverse in terms of gender and race. We measured 1,5-AG concentration in specimens collected during a double-blind, randomized trial, with repeat blood collections and multiple measurements of glucose in a population without diabetes or glucose-altering medications. This allowed us to examine the within-participant effects of diet on 1,5-AG concentrations in a population with a low likelihood of glycosuria, removing the primary determinant of 1,5-AG concentrations in people with diabetes. Furthermore, the diets were rigorously designed to isolate the effects of GI and %CHO on 1,5-AG independently of changes in weight. Finally, in a subsample as part of the original study protocol, glucose concentration was measured at multiple time points over a 12-h period, providing strong confirmation that the observed effects occurred in the absence of glucose elevations and glycosuria.
In conclusion, we found that both the type and amount of dietary carbohydrates affected 1,5-AG concentrations in a population without diabetes, which contradicts the longstanding notion that 1,5-AG remains at constant concentrations in the blood in the absence of hyperglycaemic excursions. This could have implications for the interpretation of 1,5-AG. Future studies should examine these and other dietary effects among people with and without diabetes.
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